Palmitoylated PrRP analog decreases body weight in DIO rats but not in ZDF rats
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
26906745
DOI
10.1530/joe-15-0519
PII: JOE-15-0519
Knihovny.cz E-resources
- Keywords
- ZDF rats, diet-induced obesity, food intake, lipidization, prolactin-releasing peptide, rat,
- MeSH
- Appetite Depressants pharmacology MeSH
- Diet, High-Fat adverse effects MeSH
- Diabetes Mellitus, Experimental metabolism MeSH
- Glucose Tolerance Test MeSH
- Prolactin-Releasing Hormone analogs & derivatives pharmacology MeSH
- Liver drug effects metabolism MeSH
- Rats MeSH
- Receptors, Leptin deficiency MeSH
- Lipoylation MeSH
- RNA, Messenger genetics metabolism MeSH
- Lipid Metabolism drug effects genetics MeSH
- Mice MeSH
- Obesity drug therapy metabolism pathology MeSH
- Rats, Sprague-Dawley MeSH
- Rats, Zucker MeSH
- Eating drug effects MeSH
- Drug Design MeSH
- Body Weight drug effects MeSH
- Adipose Tissue drug effects metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Appetite Depressants MeSH
- Prolactin-Releasing Hormone MeSH
- Receptors, Leptin MeSH
- RNA, Messenger MeSH
Anorexigenic neuropeptides produced and acting in the brain have the potential to decrease food intake and ameliorate obesity, but are ineffective after peripheral application, owing to a limited ability to cross the blood-brain barrier. We have designed lipidized analogs of prolactin-releasing peptide (PrRP), which is involved in energy balance regulation as demonstrated by obesity phenotypes of both Prrp-knockout and Prrp receptor-knockout mice. The aim of this study was to characterize the subchronic effect of a palmitoylated PrRP analog in two rat models of obesity and diabetes: diet-induced obese Sprague-Dawley rats and leptin receptor-deficient Zucker diabetic (ZDF) rats. In the rats with diet-induced obesity (DIO), a two-week intraperitoneal treatment with palmitoylated PrRP lowered food intake by 24% and body weight by 8%. This treatment also improved glucose tolerance and tended to decrease leptin levels and adipose tissue masses in a dose-dependent manner. In contrast, in ZDF rats, the same treatment with palmitoylated PrRP lowered food intake but did not significantly affect body weight or glucose tolerance, probably in consequence of severe leptin resistance due to a nonfunctional leptin receptor. Our data indicate a good efficacy of lipidized PrRP in DIO rats. Thus, the strong anorexigenic, body weight-reducing, and glucose tolerance-improving effects make palmitoylated PrRP an attractive candidate for anti-obesity treatment.
1st Faculty of MedicineCharles University Prague Czech Republic
References provided by Crossref.org
Prolactin-Releasing Peptide: Physiological and Pharmacological Properties
